Cargando…
A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short survival. Traditionally, risk stratification in DLBC...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175759/ https://www.ncbi.nlm.nih.gov/pubmed/37188190 http://dx.doi.org/10.3389/fonc.2023.1157646 |
_version_ | 1785040280870715392 |
---|---|
author | Mosquera Orgueira, Adrián Díaz Arías, Jose Ángel Serrano Martín, Rocio Portela Piñeiro, Victor Cid López, Miguel Peleteiro Raíndo, Andrés Bao Pérez, Laura González Pérez, Marta Sonia Pérez Encinas, Manuel Mateo Fraga Rodríguez, Máximo Francisco Vallejo Llamas, Juan Carlos Bello López, José Luis |
author_facet | Mosquera Orgueira, Adrián Díaz Arías, Jose Ángel Serrano Martín, Rocio Portela Piñeiro, Victor Cid López, Miguel Peleteiro Raíndo, Andrés Bao Pérez, Laura González Pérez, Marta Sonia Pérez Encinas, Manuel Mateo Fraga Rodríguez, Máximo Francisco Vallejo Llamas, Juan Carlos Bello López, José Luis |
author_sort | Mosquera Orgueira, Adrián |
collection | PubMed |
description | Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short survival. Traditionally, risk stratification in DLBCL has been based on scores that combine clinical variables. Other methodologies have been developed based on the identification of novel molecular features, such as mutational profiles and gene expression signatures. Recently, we developed the LymForest-25 profile, which provides a personalized survival risk prediction based on the integration of transcriptomic and clinical features using an artificial intelligence system. In the present report, we studied the relationship between the molecular variables included in LymForest-25 in the context of the data released by the REMoDL-B trial, which evaluated the addition of bortezomib to the standard treatment (R-CHOP) in the upfront setting of DLBCL. For this, we retrained the machine learning model of survival on the group of patients treated with R-CHOP (N=469) and then made survival predictions for those patients treated with bortezomib plus R-CHOP (N=459). According to these results, the RB-CHOP scheme achieved a 30% reduction in the risk of progression or death for the 50% of DLBCL patients at higher molecular risk (p-value 0.03), potentially expanding the effectiveness of this treatment to a wider patient population as compared with other previously defined risk groups. |
format | Online Article Text |
id | pubmed-10175759 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101757592023-05-13 A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma Mosquera Orgueira, Adrián Díaz Arías, Jose Ángel Serrano Martín, Rocio Portela Piñeiro, Victor Cid López, Miguel Peleteiro Raíndo, Andrés Bao Pérez, Laura González Pérez, Marta Sonia Pérez Encinas, Manuel Mateo Fraga Rodríguez, Máximo Francisco Vallejo Llamas, Juan Carlos Bello López, José Luis Front Oncol Oncology Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short survival. Traditionally, risk stratification in DLBCL has been based on scores that combine clinical variables. Other methodologies have been developed based on the identification of novel molecular features, such as mutational profiles and gene expression signatures. Recently, we developed the LymForest-25 profile, which provides a personalized survival risk prediction based on the integration of transcriptomic and clinical features using an artificial intelligence system. In the present report, we studied the relationship between the molecular variables included in LymForest-25 in the context of the data released by the REMoDL-B trial, which evaluated the addition of bortezomib to the standard treatment (R-CHOP) in the upfront setting of DLBCL. For this, we retrained the machine learning model of survival on the group of patients treated with R-CHOP (N=469) and then made survival predictions for those patients treated with bortezomib plus R-CHOP (N=459). According to these results, the RB-CHOP scheme achieved a 30% reduction in the risk of progression or death for the 50% of DLBCL patients at higher molecular risk (p-value 0.03), potentially expanding the effectiveness of this treatment to a wider patient population as compared with other previously defined risk groups. Frontiers Media S.A. 2023-04-28 /pmc/articles/PMC10175759/ /pubmed/37188190 http://dx.doi.org/10.3389/fonc.2023.1157646 Text en Copyright © 2023 Mosquera Orgueira, Díaz Arías, Serrano Martín, Portela Piñeiro, Cid López, Peleteiro Raíndo, Bao Pérez, González Pérez, Pérez Encinas, Fraga Rodríguez, Vallejo Llamas and Bello López https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Mosquera Orgueira, Adrián Díaz Arías, Jose Ángel Serrano Martín, Rocio Portela Piñeiro, Victor Cid López, Miguel Peleteiro Raíndo, Andrés Bao Pérez, Laura González Pérez, Marta Sonia Pérez Encinas, Manuel Mateo Fraga Rodríguez, Máximo Francisco Vallejo Llamas, Juan Carlos Bello López, José Luis A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma |
title | A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma |
title_full | A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma |
title_fullStr | A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma |
title_full_unstemmed | A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma |
title_short | A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma |
title_sort | prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large b-cell lymphoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175759/ https://www.ncbi.nlm.nih.gov/pubmed/37188190 http://dx.doi.org/10.3389/fonc.2023.1157646 |
work_keys_str_mv | AT mosqueraorgueiraadrian aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT diazariasjoseangel aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT serranomartinrocio aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT portelapineirovictor aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT cidlopezmiguel aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT peleteiroraindoandres aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT baoperezlaura aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT gonzalezperezmartasonia aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT perezencinasmanuelmateo aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT fragarodriguezmaximofrancisco aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT vallejollamasjuancarlos aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT bellolopezjoseluis aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT mosqueraorgueiraadrian prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT diazariasjoseangel prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT serranomartinrocio prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT portelapineirovictor prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT cidlopezmiguel prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT peleteiroraindoandres prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT baoperezlaura prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT gonzalezperezmartasonia prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT perezencinasmanuelmateo prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT fragarodriguezmaximofrancisco prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT vallejollamasjuancarlos prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT bellolopezjoseluis prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma |